# Yantai Rongchang Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yantai-rongchang-pharmaceutical

- Industry: Pharmaceuticals
- Headquarters: Yantai, China
- Website: www.rongchang.com
- Total disclosed funding: $52M
- Latest round: Series B (Sep 1, 2017)
- Investors on record: 4

## About

Based in Yantai, China and established in 1993, Yantai Rongchang Pharmaceutical is a modern pharmaceutical enterprise with a presence in modern Chinese medicine, small molecule and bio-pharmaceuticals, CDMO services, and incubation of bio-pharmaceutical enterprises and projects. The company has 94 drug registration numbers and 70 patents, and passed the GMP certification of the Ministry of Health in 1998. In 2010, the company acquired Shandong Lutai Huanzhong Pharmaceutical Co. In December 2017, the company raised CNY 1 billion in a round of strategic investment.

The company focuses on traditional Chinese medicine and innovative pharmaceuticals, offering a range of products including those for anorectal diseases, neurological and psychiatric conditions, and cardiovascular health. Notable products include "Gangtai" for anorectal issues and the first-in-class "Endostar" for anti-cancer treatment, which was approved by the National Medical Products Administration.

The company generates revenue by selling pharmaceutical products and providing CDMO services to clients in the healthcare industry.

## Funding rounds

- Series B, Sep 1, 2017, $52M — PAG
- Series A, Dec 1, 2006 — China Science & Merchants Capital Management, Mingxin Capital, Yantai Venture

## Investors

- China Science & Merchants Capital Management (https://capitalatlas.ai/funds/china-science-merchants-capital-management) — Series A
- Mingxin Capital (https://capitalatlas.ai/funds/mingxin-capital) — Series A
- Yantai Venture — Series A
- PAG (https://capitalatlas.ai/funds/pag) — Series B